For research use only. Not for human consumption. · Nationwide shipping · 18+

NVNuVida Vital
Shop
Semaglutide — lyophilized powder in a sealed glass vial with crimp sealLyophilized powder

Semaglutide

Semaglutide (GLP-1 receptor agonist)

Semaglutide is a 31-amino-acid GLP-1 analog structurally modified at position 8 (Aib substitution) to resist DPP-4 degradation, with a C18 fatty diacid chain conjugated via a spacer at Lys26 that promotes albumin binding. These modifications extend its half-life substantially relative to native GLP-1, which has a circulating half-life measured in minutes. It is among the most heavily published peptides in modern metabolic research.

Research applications

  • Incretin receptor signaling and β-cell response studies
  • Gastric emptying and satiety-pathway research in rodent models
  • Comparative pharmacokinetics against dual and triple agonists
  • Receptor binding affinity and selectivity assays

Storage

Store lyophilized powder at -20°C protected from light. Reconstituted solution is stable at 2-8°C for up to 30 days.

Reconstitution

Reconstitute with bacteriostatic water directed slowly down the vial wall. Do not shake — agitation causes peptide denaturation. Swirl gently until fully dissolved.

Published literature

6,619 papers indexed on PubMed for Semaglutide. Showing 6, reviews first.

  1. 01
    Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation

    Moiz A et al. · Am J Med · 2025

    ReviewPMID 39892489doi:10.1016/j.amjmed.2025.01.021

  2. 02
    What is the pipeline for future medications for obesity?

    Melson E et al. · Int J Obes (Lond) · 2025

    ReviewPMID 38302593doi:10.1038/s41366-024-01473-y

  3. 03
    GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis

    Singh A et al. · World J Gastroenterol · 2024

    ReviewPMID 39735270doi:10.3748/wjg.v30.i48.5205

  4. 04
    Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

    Nauck MA, D'Alessio DA · Cardiovasc Diabetol · 2022

    ReviewPMID 36050763doi:10.1186/s12933-022-01604-7

  5. 05
    The Discovery and Development of Liraglutide and Semaglutide

    Knudsen LB, Lau J · Front Endocrinol (Lausanne) · 2019

    ReviewPMID 31031702doi:10.3389/fendo.2019.00155

  6. 06
    Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity

    Rodriguez PJ et al. · JAMA Netw Open · 2025

    PMID 39888616doi:10.1001/jamanetworkopen.2024.57349

Indexed from PubMed, 2026-07-19. We link to sources rather than reproducing them.

Read the full Semaglutide research reference →

Related compounds

Tirzepatide — lyophilized powder in a sealed glass vial

Tirzepatide

10–30mg · ≥99% pure

Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.

CAS
2023788-19-2
MW
4813.45
Purity
≥99%
In stock
From$89
Retatrutide — lyophilized powder in a sealed glass vialLow stock

Retatrutide

10–30mg · ≥99% pure

Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.

CAS
2381089-83-2
MW
4731.32
Purity
≥99%
6 left
From$99
Cagrilintide — lyophilized powder in a sealed glass vial

Cagrilintide

10mg · ≥99% pure

Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.

CAS
1415456-99-3
MW
4409
Purity
≥99%
In stock
From$99
AOD-9604 — lyophilized powder in a sealed glass vial

AOD-9604

5mg · ≥99% pure

C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.

CAS
221231-10-3
MW
1815.08
Purity
≥99%
In stock
From$44